Revisiting secondary mitral regurgitation threshold severity: insights and lessons from the RESHAPE-HF2 trial
Open Access
- 31 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (5) , oeae084
Abstract
This article revisits the severity threshold for secondary mitral regurgitation (MR), focusing on insights and lessons from the RESHAPE-HF2 trial. It aims to challenge the traditional effective regurgitant orifice area (EROA) threshold of ≥0.40 cm2 used for intervention, suggesting that earlier intervention may benefit patients with lower EROA. It also explores how transcatheter edge-to-edge repair (TEER) improves outcomes in patients with secondary MR and assesses the impact of left ventricular (LV) remodeling on treatment success. The RESHAPE-HF2 trial evaluated the use of TEER in patients with moderate-to-severe secondary MR, comparing outcomes in those with an EROA ≥0.2 cm2 and no extensive LV remodeling. TEER significantly reduced heart failure hospitalizations and improved quality of life in these patients. This supports the notion that patients with less severe MR, who still show symptoms despite optimal medical therapy, may benefit from earlier intervention. Comparisons with COAPT and MITRA-FR trials underscored the importance of selecting patients based on MR severity relative to LV dilatation. The RESHAPE-HF2 trial highlights the need to reconsider the current EROA threshold for secondary MR intervention. TEER has shown to be beneficial even in patients with lower MR severity, suggesting that earlier intervention could improve outcomes. A more dynamic and integrated approach, considering both MR severity and LV remodeling, is essential for optimizing patient selection and treatment success.Keywords
This publication has 26 references indexed in Scilit:
- Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Comparison to COAPT and MITRA-FR TrialsEuropean Journal of Heart Failure, 2024
- Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart FailureJACC, 2022
- Mitral regurgitation severity dynamic during acute decompensated heart failure treatmentThe International Journal of Cardiovascular Imaging, 2021
- COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip ImplantationJACC: Cardiovascular Interventions, 2021
- Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral RegurgitationJACC, 2019
- A Unifying Concept for the Quantitative Assessment of Secondary Mitral RegurgitationJACC, 2019
- Proportionate and Disproportionate Functional Mitral RegurgitationJACC: Cardiovascular Imaging, 2019
- Defining “Severe” Secondary Mitral RegurgitationJACC, 2014
- Left Ventricle Volume Affects the Result of Mitral Valve Surgery for Idiopathic Dilated Cardiomyopathy to Treat Congestive Heart FailureThe Annals of Thoracic Surgery, 2006
- Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunctionJACC, 2003